NASDAQ:IMRA

IMARA Competitors

$7.29

-0.38 (-4.95 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.26

Now: $7.29▼

$7.64

50-Day Range

$7.67

MA: $10.05▼

$13.86

52-Week Range

$7.26

Now: $7.29▼

$62.71

Volume107,155 shs

Average Volume158,507 shs

Market Capitalization$128.12 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

IMARA (NASDAQ:IMRA) Vs. MRNS, RAPT, AKUS, AMYT, AVDL, and XBIT

Should you be buying IMRA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IMARA, including Marinus Pharmaceuticals (MRNS), RAPT Therapeutics (RAPT), Akouos (AKUS), Amryt Pharma (AMYT), Avadel Pharmaceuticals (AVDL), and XBiotech (XBIT).

IMARA vs. Marinus Pharmaceuticals Stock

Marinus Pharmaceuticals (NASDAQ:MRNS) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

79.3% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. 2.8% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Marinus Pharmaceuticals and IMARA's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marinus Pharmaceuticals	N/A	N/A	$-54,120,000.00	($3.96)	-3.53
IMARA	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Marinus Pharmaceuticals and IMARA's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marinus Pharmaceuticals	N/A	-95.56%	-66.01%
IMARA	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Marinus Pharmaceuticals and IMARA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marinus Pharmaceuticals	0	0	9	0	3.00
IMARA	0	0	3	0	3.00

Marinus Pharmaceuticals currently has a consensus price target of $28.75, indicating a potential upside of 105.50%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's higher possible upside, analysts plainly believe IMARA is more favorable than Marinus Pharmaceuticals.

IMARA vs. RAPT Therapeutics Stock

RAPT Therapeutics (NASDAQ:RAPT) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

65.0% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares RAPT Therapeutics and IMARA's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RAPT Therapeutics	N/A	N/A	$-43,000,000.00	($9.89)	-2.05
IMARA	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares RAPT Therapeutics and IMARA's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RAPT Therapeutics	N/A	-48.78%	-42.35%
IMARA	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for RAPT Therapeutics and IMARA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RAPT Therapeutics	0	0	5	0	3.00
IMARA	0	0	3	0	3.00

RAPT Therapeutics currently has a consensus price target of $41.20, indicating a potential upside of 103.06%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's higher possible upside, analysts plainly believe IMARA is more favorable than RAPT Therapeutics.

IMARA vs. Akouos Stock

Akouos (NASDAQ:AKUS) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

88.7% of Akouos shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Akouos and IMARA's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akouos	N/A	N/A	N/A	N/A	N/A
IMARA	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Akouos and IMARA's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akouos	N/A	N/A	N/A
IMARA	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Akouos and IMARA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akouos	0	1	3	0	2.75
IMARA	0	0	3	0	3.00

Akouos currently has a consensus price target of $31.6667, indicating a potential upside of 118.24%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's stronger consensus rating and higher possible upside, analysts plainly believe IMARA is more favorable than Akouos.

Summary

IMARA beats Akouos on 2 of the 3 factors compared between the two stocks.

IMARA vs. Amryt Pharma Stock

Amryt Pharma (NASDAQ:AMYT) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Amryt Pharma and IMARA's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amryt Pharma	N/A	N/A	N/A
IMARA	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Amryt Pharma and IMARA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amryt Pharma	0	1	3	0	2.75
IMARA	0	0	3	0	3.00

Amryt Pharma currently has a consensus price target of $38.00, indicating a potential upside of 174.37%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's stronger consensus rating and higher possible upside, analysts plainly believe IMARA is more favorable than Amryt Pharma.

Valuation and Earnings

This table compares Amryt Pharma and IMARA's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amryt Pharma	$58.12 million	8.55	$-30,854,220.00	($0.86)	-16.11
IMARA	N/A	N/A	N/A	N/A	N/A

IMARA has lower revenue, but higher earnings than Amryt Pharma.

Institutional and Insider Ownership

15.4% of Amryt Pharma shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

IMARA beats Amryt Pharma on 3 of the 4 factors compared between the two stocks.

IMARA vs. Avadel Pharmaceuticals Stock

IMARA (NASDAQ:IMRA) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares IMARA and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMARA	N/A	N/A	N/A
Avadel Pharmaceuticals	38.70%	-33.91%	-11.75%

Analyst Ratings

This is a summary of recent ratings for IMARA and Avadel Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMARA	0	0	3	0	3.00
Avadel Pharmaceuticals	0	0	6	0	3.00

IMARA presently has a consensus price target of $35.3333, suggesting a potential upside of 384.68%. Avadel Pharmaceuticals has a consensus price target of $18.60, suggesting a potential upside of 120.38%. Given IMARA's higher possible upside, equities analysts clearly believe IMARA is more favorable than Avadel Pharmaceuticals.

Valuation & Earnings

This table compares IMARA and Avadel Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMARA	N/A	N/A	N/A	N/A	N/A
Avadel Pharmaceuticals	$59.22 million	8.33	$-33,230,000.00	($0.89)	-9.48

IMARA has higher earnings, but lower revenue than Avadel Pharmaceuticals.

Institutional & Insider Ownership

64.5% of IMARA shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 1.4% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

IMARA vs. XBiotech Stock

IMARA (NASDAQ:IMRA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares IMARA and XBiotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMARA	N/A	N/A	N/A
XBiotech	N/A	-7.07%	-6.67%

Analyst Ratings

This is a summary of recent ratings for IMARA and XBiotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMARA	0	0	3	0	3.00
XBiotech	0	0	0	0	N/A

IMARA presently has a consensus price target of $35.3333, suggesting a potential upside of 384.68%. Given IMARA's higher possible upside, equities analysts clearly believe IMARA is more favorable than XBiotech.

Valuation & Earnings

This table compares IMARA and XBiotech's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMARA	N/A	N/A	N/A	N/A	N/A
XBiotech	N/A	N/A	$668.63 million	N/A	N/A

Institutional & Insider Ownership

64.5% of IMARA shares are held by institutional investors. Comparatively, 14.8% of XBiotech shares are held by institutional investors. 31.0% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

IMARA beats XBiotech on 5 of the 6 factors compared between the two stocks.